Severe ceftriaxone-induced hemolysis complicated by diffuse cerebral ischemia in a child with sickle cell disease.
Ceftriaxone-induced hemolytic anemia is a rare and often fatal phenomenon. We report here the case of a 6-year-old female with sickle cell disease who survived a brisk and profound hemolytic reaction, resulting in hemoglobin of 0.4 g/dL, after ceftriaxone infusion. Ongoing hemolysis was abrogated with aggressive supportive care, but the patient suffered extensive neurologic sequelae as a result of the event. Serologic testing confirmed the presence of ceftriaxone antibodies.
Schuettpelz
Laura G
LG
Division of Hematology and Oncology, Department of Pediatrics, Washington University School of Medicine, St Louis, MO 63110, USA. schuettpelz_l@kids.wustl.edu
Behrens
Deanna
D
Goldsmith
Matthew I
MI
Druley
Todd E
TE
D000743:Anemia, Hemolytic / Q000097:blood / Q000139:chemically induced* / Q000276:immunology / Q000628:therapy; D000755:Anemia, Sickle Cell / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D000906:Antibodies / Q000097:blood / Q000276:immunology; D002545:Brain Ischemia / Q000097:blood / Q000139:chemically induced* / Q000276:immunology / Q000628:therapy; D002443:Ceftriaxone / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D002648:Child; D005260:Female; D006461:Hemolysis / Q000187:drug effects*; D006801:Humans
D000900:Anti-Bacterial Agents; D000906:Antibodies; D002443:Ceftriaxone